WRLD A.LIVE

01:002 reports

• New Device Targets Nerve Signals To Treat Cancer-Related Wasting, Moving To First Human Trial News-Medical
• /C O R R E C T I O N — Privo Technologies/ Morningstar

00:0015 reports

• How pancreatic cancers respond to treatment: insights from spatial multiomics Nature
• High expression of CTDNEP1 gene linked to poorer kidney cancer survival News-Medical
• HMGA1 and HMGA2 : epigenetic regulators in myeloproliferative neoplasms and novel platelet transcriptomic biomarkers of myelofibrosis Nature
• Privo Technologies' PRV111 clears early-stage oral cancer in 95.5% of patients in Phase 2 Dealroom
• Cancer Survivors Have Lower Levels of Physical Activity Infectious Disease Advisor
• Exercise Gave Me Control. It Didn’t Cure My Cancer Cure Today
• Breast cancer survivors needed for FAU research study The Palm Beach Post
• Exercise therapy in cancer prevention and treatment Nature
• It Can Keep Cancer in Remission. Why Is No One Talking About It? The New York Times
• PRV111 Shows Strong Responses in Early Oral Cancer Targeted Oncology
• Clinical Update from the Ongoing Phase 2 Trial of PRV111, the First Non-Surgical Therapy in Development for Early-Stage Oral Cancer BioSpace
• Privo’s cisplatin patch shows potential to spare oral cancer surgery AllSci
• Cisplatin-Releasing PRV111 Patch Elicits High pCR Rate in Early-Stage Oral Cancer OncLive
• Transmucosal Patch Yields Pathologic Responses in Non-Invasive Oral Cancer CancerNetwork
• Practical Pathological Assessment of Residual Cancer Burden (RCB) After Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Invasive Breast Carcinoma: A Case Report Cureus

23:009 reports

• Patient-Derived GBM Organoid Platform Probes Radiation and Drug Responses Inside Precision Medicine
• Newly uncovered enzyme mechanism could help target drug-resistant breast cancer Medical Xpress
• Nuclear enzyme discovery unlocks new paths to combat breast cancer News-Medical
• Science Spotlight: CDK4/6 resistance that a mutation panel can’t see BioCentury Inc.
• Enzyme Biomarker May Predict CDK4/6 Inhibitor Resistance in Breast Cancer Inside Precision Medicine
• Key Driver of Aggressive Prostate Cancer Identified, Suggesting New Way to Reverse Drug Resistance | Newswise Newswise
• Key driver of aggressive prostate cancer identified, suggesting new way to reverse drug resistance Medical Xpress
• tRNA dosage regulates lineage dependency and resistance in prostate cancer Nature
• tRNA Influences If Prostate Cancer Becomes Resistant to Treatment Inside Precision Medicine

22:002 reports

• Gene expression linked to survival differs by kidney cancer subtype Medical Xpress
• Study reveals link between mtDNA copy number and cancer severity News-Medical

21:002 reports

• Cancer Drug in Trials May Work Differently Than Scientists Thought, Raising Concerns Technology Networks
• RF-DETR with multi-scale feature fusion and explainable attention for accurate brain tumor detection in MRI Nature

20:001 report

• A scalable Zebrafish Platform for genetic validation and functional discovery of stage-specific breast cancer metastasis regulators Nature

19:001 report

• Cancer trial drug may work differently than scientists believed, raising concerns for clinical research Innovation News Network

18:001 report

• The chromatin-organizer Satb1 modulates regulatory T cell activity within the tumor microenvironment Nature

17:002 reports

• Mitochondrial DNA levels reveal links to tumor growth and chemotherapy-related gene activity Medical Xpress
• Developing Novel Cancer Therapy That Disrupts Communication Between Cancer Cells and Cancer-associated fibroblasts Asia Research News |

16:00nothing heard

15:00nothing heard

14:001 report

• A CAVIN1 SULF1 -associated myCAF signature predicts metastatic progression in colorectal cancer Nature

13:00nothing heard

12:00nothing heard

11:001 report

• Leor Weinberger, PhD, earns NIH Director’s Pioneer Award to tackle evolving cancers. [IMAGE] EurekAlert! Science News Releases Pioneer